BMO Capital Downgrades Globus Medical to Market Perform, Cuts Target to $78
The firm cut its price target to $78 from $94, down from a prior median target of $99 across 13 firms covering the stock.
Globus Medical GMED
Globus Medical Inc · NYSE · Surgical & Medical Instruments & Apparatus
$75.39+0.21%close on Nov. 11, 2026 · volume 1.9M · Yahoo Finance
Price, last 57 sessions
Our coverage
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Nov. 4, 2026 | Ann D. Rhoads director | Sold 10b5-1 plan | 5,000 | $85.00 | $425,000 |
| Sept. 15, 2026 | James R. Tobin director | Sold | 30,000 | $74.58 | $2.24 million |
| Aug. 18, 2026 | Stephen T. Zarrilli director | Sold | 25,000 | $87.04 | $2.18 million |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 10 →Results of operations and financial condition · Other events · Financial statements and exhibits
AI summary, unreviewedGlobus Medical Q3 2026 non-GAAP EPS of $1.23 beats $1.20 consensus, but revenue of $763.7 million misses $792.5 million and full-year revenue guidance is cut to $3.09 billion